ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026
Pre-treatment audiological and vestibular assessment in adults starting platinum-based chemotherapy.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeTo evaluate the feasibility of incorporating both standard and novel audiological and vestibular assessments into routine oncology care. A secondary objective was to characterize audiovestibular status prior to platinum-based chemotherapy and identify potential risk factors for cochleotoxicity and vestibulotoxicity.
methodThis single-center, cross-sectional prospective study enrolled 110 adults scheduled for their first platinum-based chemotherapy cycle. All assessments were performed at one time point prior to treatment initiation. Pre-treatment assessments included tympanometry, pure-tone audiometry, speech audiometry in quiet and noise (SPIQ and SPIN), distortion product otoacoustic emissions (DPOAEs), auditory brainstem responses (ABRs), envelope following responses (EFRs), video head impulse testing (vHIT), and cervical vestibular evoked myogenic potentials (cVEMP).
resultsAll patients underwent tympanometry and pure-tone audiometry. A broader audiological test battery was completed in 96 patients (87.3%). At least one vestibular assessment was performed in 65 patients (59.1%). Completion of the protocol was limited by age, fatigue, or logistical constraints. Vestibular assessments were sometimes hindered by physical and time limitations. Before the start of chemotherapy, hearing loss was present in 44.5% of patients (30.9% bilateral, 13.6% unilateral), while 9.1% reported tinnitus and 34.5% reported difficulty understanding speech in noise. Speech audiometry (SPIQ and SPIN SRTs) revealed significant differences between age groups, with post-hoc analysis showing differences between the 34-57 group and the older groups. DPOAE amplitudes were significantly different across age groups at 1500 Hz, 2000 Hz, 3000 Hz, 4000 Hz, and 6000 Hz. EFR magnitudes, as well as ABR amplitudes and latencies, did not differ significantly between age groups. At baseline, three patients were diagnosed with benign paroxysmal positional vertigo (BPPV). vHIT revealed vestibulo-ocular reflex (VOR) gain deficits in three patients. cVEMP responses were absent bilaterally in three patients and unilaterally in one.
conclusionAudiological assessments were largely feasible, even in older adults, and revealed pre-existing audiovestibular deficits including high-frequency hearing loss and BPPV. Given risk factors such as advanced age, baseline hearing deficits, and planned type of platinum-based chemotherapy, this population is particularly vulnerable to cochleotoxicity. These findings support implementing a pre-treatment audiovestibular protocol that can serve as a baseline for subsequent longitudinal ototoxicity monitoring, with individualized adaptations to optimize feasibility and to support early detection of ototoxic changes and timely intervention during follow-up.
Indexed as
Identifiers
41925873What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.